Instrument Inactif

Communiqués ArQule, Inc.

Actions

US04269E1073

Recherche biotechnologique et médicale

Communiqués

13/11/20	ArQule : Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors	AQ
16/01/20	ARQULE INC : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
17/12/19	ARQULE INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
09/12/19	ARQULE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARQL and Encourages Investors to Contact the Firm	PR
09/12/19	ArQule : Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	BU
09/12/19	(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price?	PR
09/12/19	ARQULE INC : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
25/11/19	ArQule : to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	BU
20/11/19	ARQULE INC : Amendment or Waiver to Code of Ethics (form 8-K)	AQ
13/11/19	ArQule : to Participate in the Jefferies London Healthcare Conference on November 20, 2019	BU
06/11/19	ArQule : Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies	BU
30/10/19	ArQule : Reports Third Quarter 2019 Financial Results	BU
29/10/19	ArQule : Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	BU
21/10/19	ArQule : Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting	BU
16/10/19	ArQule : Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	BU
16/10/19	ArQule : to Report Third Quarter 2019 Financial Results on October 30, 2019	BU
08/10/19	ArQule : to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting	PU
08/10/19	ArQule : ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting	BU
02/10/19	ArQule : Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum	BU
26/09/19	ArQule : to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019	BU
17/09/19	ArQule : to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019	BU
28/08/19	ArQule : to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019	BU
07/08/19	ArQule : Reports Second Quarter 2019 Financial Results	BU
05/08/19	ArQule : to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019	BU
01/08/19	ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019	BU